Chiome Bioscience

Basic Information

Stock Code
4583
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
February 2005
Listing Year
December 2011
Official Website
https://www.chiome.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GN I Group, Heartseed, Nexera Pharma, DWTI, Kids Bio, Peptidream, SanBio, Helios, Fanpep, Rena Science, QualiPs, Takara Bio, Japan Tissue Engineering

Overview

Chiome Bioscience is a biopharmaceutical company founded in 2005 and based in Tokyo, specializing in the discovery and research & development of antibody therapeutics, leveraging biotechnology for innovative drug development to hold a competitive position within the industry.

Current Situation

In 2023, Chiome Bioscience steadily advanced its R&D efforts, maintaining several development pipelines in the antibody therapeutics field. Financially stable with consistent funding, it actively engages in joint research with external companies. Its core business involves providing antibody discovery platforms and developing proprietary antibody drug candidates, establishing a solid position in the biotech and pharmaceutical market. In technology development, it focuses on antibody engineering to enable efficient antibody production and improvement. Environmentally and socially, it promotes sustainable research operations and local community contributions. Toward 2030, it aims to out-license new drugs to global markets and expand innovation. Recently, it has strengthened collaborations with domestic and international venture companies and focused on biomarker research to gain competitive advantages in next-generation drug development.

Trivia

Interesting Facts

  • One of the pioneering companies in Japan for antibody drug discovery technology
  • Rapid increase in patent acquisitions since the 2020s
  • Possesses an in-house specialized antibody engineering lab
  • Owns multiple company labs and testing facilities in Tokyo
  • Joint research network spans domestic and international
  • Some research outcomes highly evaluated at international conferences
  • President is a renowned researcher from the antibody therapeutics industry
  • Sustained stable growth as a biotech venture since listing
  • Antibody production technology serves as benchmark for many domestic companies
  • Actively promotes open innovation
  • Top-class number of patents for new antibody technologies in Japan
  • Technical training programs in collaboration with medical education institutions
  • Extensive track record of presentations at various academic societies
  • Possesses one of Japan's largest antibody libraries
  • Reputation for speed in adopting new technologies

Hidden Connections

  • Has entered into antibody joint research contracts with many domestic pharmaceutical companies to strengthen its technology base.
  • In capital alliance with prominent U.S. biotech venture to accelerate overseas expansion.
  • Numerous collaborations with universities and national institutes, with active sharing of research outcomes.
  • Many in-house researchers have overseas study abroad experience, maintaining an international perspective.
  • Technology for some products provided to Southeast Asian markets via patent licensing.
  • Strong sales partnership with domestic pharmaceutical wholesalers.
  • Advances development of innovative treatments through collaborations with medical startups.
  • Key antibody production technology used as teaching material in science education institutions nationwide.

Future Outlook

Growth Drivers

  • Global expansion of antibody therapeutics market
  • Promotion of next-generation biotech practical applications
  • Increasing medical needs due to aging society
  • Expansion of domestic and international joint research and capital alliances
  • Improvement in global pharmaceutical approval systems
  • Drug discovery efficiency gains from AI and digital technology integration
  • Increased clinical applications of biomarker technology
  • Regulatory easing and expanded government support
  • Antibody technology applications to diverse disease areas
  • Product personalization based on patient needs
  • Rising pharmaceutical demand in international markets
  • Growing support for environmentally considerate R&D

Strategic Goals

  • Obtain global approvals for key antibody therapeutics
  • Aim to surpass 10 billion yen in sales
  • Complete company-wide introduction of AI drug discovery technology
  • Halve energy use and environmental impact in labs
  • Expand pipelines with overseas partners
  • Strengthen technology deployment to new disease areas
  • Expand market share in biomarker business
  • Significantly increase female researcher ratio
  • Rank in top tier of domestic ESG evaluations
  • Achieve doubling of patent acquisitions

Business Segments

Antibody Drug Discovery Platform Provision

Overview
Provides antibody drug discovery support technologies and services to development companies and research institutions.
Competitiveness
Possesses proprietary antibody production efficiency technology enabling rapid drug discovery support.
Customers
  • Pharmaceutical companies
  • Biotechnology companies
  • University research institutions
  • Public research institutions
  • Drug discovery ventures
  • Global pharmaceutical companies
  • Healthcare technology companies
Products
  • Antibody production services
  • Antibody modification technology
  • Antibody library provision
  • Antibody screening technology
  • Drug discovery support platform
  • Immune response analysis tools

New Antibody Therapeutics Development

Overview
Engages in R&D and clinical introduction of new antibody therapeutics.
Competitiveness
High technological capabilities and development system focused on clinical applications.
Customers
  • Pharmaceutical development companies
  • Wholesalers
  • Biotech and medical device companies
  • Clinical trial institutions
  • R&D partners
Products
  • Antibody therapeutic candidates
  • Biomarker development
  • Clinical trial drug supply
  • Immune checkpoint therapeutics
  • Bispecific antibodies

Technology Licensing Provision

Overview
Conducts licensing of antibody technologies and drug discovery support technologies.
Competitiveness
Competitive advantage through extensive patent portfolio.
Customers
  • Domestic and international pharmaceutical companies
  • Biotech ventures
  • University research institutions
Products
  • Antibody technology licenses
  • Drug discovery platform usage rights
  • Provision of patented technologies

Contract Research Services

Overview
Provides contract research evaluation for antibody therapeutics.
Competitiveness
Contract system leveraging advanced analytical technologies and extensive experience.
Customers
  • Pharmaceutical development companies
  • Research institutions
  • Biotech companies
Products
  • Antibody evaluation services
  • Functional testing
  • Safety testing

Biomarker Development Support

Overview
Supports biomarker development for drug discovery and diagnostics.
Competitiveness
High-sensitivity detection and analysis capabilities through proprietary technologies.
Customers
  • Pharmaceutical companies
  • Diagnostic drug manufacturers
  • Research institutions
Products
  • Biomarker detection technology
  • Drug discovery target analysis
  • Data analysis services

Pharmaceutical Manufacturing Technology Development

Overview
Develops and provides support technologies for improving efficiency and quality in antibody therapeutic manufacturing.
Competitiveness
Know-how in stable manufacturing technologies based on experience.
Customers
  • Pharmaceutical manufacturing companies
  • Contract manufacturers
Products
  • Manufacturing process optimization
  • Quality control technology
  • Scale-up support

Joint R&D Business

Overview
Conducts joint research and development projects on cutting-edge technologies.
Competitiveness
Collaboration capabilities with diverse expert groups.
Customers
  • Pharmaceutical companies
  • Academia
  • Technology development ventures
Products
  • New drug discovery technology research
  • Joint clinical trial advancement
  • Next-generation antibody development

Diagnostic Drug Technology Provision

Overview
Provides antibody technologies and products for the diagnostic drug field.
Competitiveness
High-precision antibody production technology.
Customers
  • Diagnostic drug manufacturers
  • Medical institutions
  • Testing centers
Products
  • Antibody-based diagnostic drug development
  • Test kit manufacturing
  • Clinical testing support

Antibody-Related Equipment Development

Overview
Develops and provides equipment for antibody research and manufacturing.
Competitiveness
Product performance enhancement through proprietary technology applications.
Customers
  • Research institutions
  • Reagent manufacturers
Products
  • Antibody purification devices
  • Quality testing equipment

International Market Business Expansion

Overview
Promotes global dissemination of drug discovery technologies through international collaborations.
Competitiveness
Global infrastructure and local partner collaborations.
Customers
  • Overseas pharmaceutical companies
  • International research institutions
Products
  • Overseas licensing
  • International joint research
  • Overseas market development

Pharmaceutical Regulatory Compliance Support

Overview
Provides technical support for regulatory compliance in pharmaceutical development.
Competitiveness
Know-how and experience based on regulatory requirements.
Customers
  • Pharmaceutical companies
  • Testing labs
  • Regulatory agencies
  • CRO
Products
  • Regulatory application support
  • Quality testing standard compliance
  • Document preparation support

Research Antibody Provision

Overview
Provides antibody products and services for basic research.
Competitiveness
High-quality research product lineup.
Customers
  • Academic institutions
  • Pharmaceutical companies
  • Biotech researchers
Products
  • Research monoclonal antibodies
  • Goto technology application products

Competitive Advantage

Strengths

  • Advanced antibody drug discovery technology
  • Diverse development pipeline holdings
  • Strong R&D team
  • Robust patent portfolio
  • Highly regarded brand in the industry
  • Advanced molecular design capabilities
  • Flexible joint research framework
  • Stable funding capabilities
  • Convenience of Tokyo base
  • Strong academic and corporate collaborations
  • Proprietary antibody library
  • Comprehensive capabilities from research to commercialization
  • Global expansion orientation
  • Sustainable research operations
  • Extensive experience of specialized technicians

Competitive Advantages

  • Suppresses development costs with high-efficiency antibody production technology
  • Strong partnership ties with domestic and international pharmaceutical companies
  • Possesses proprietary bispecific antibody technology
  • Pipeline adaptable to wide range of therapeutic areas
  • Market protection through excellent IP management and patent strategy
  • Competitive edge via rapid drug discovery processes
  • Differentiated product development using multi-form antibody technology
  • Technological innovation and risk diversification through joint research
  • Integrated support system from R&D to regulatory compliance
  • Ongoing innovation via continuous adoption of latest biotech
  • Capabilities for international market entry
  • Agile organizational operations and decision-making
  • High-quality research by specialized teams
  • Strategic investments leveraging external funding
  • Problem-solving abilities specific to pharmaceutical development

Threats

  • Intensifying competition with major pharmaceutical companies
  • Risk of technology obsolescence due to rapid biotech advances
  • Delays in clinical trials or regulatory approvals
  • Research stagnation from deteriorating funding environment
  • Patent infringement issues with competitors
  • Changes in operating environment of external partners
  • Impacts from global political and economic instability
  • Sudden shifts in market needs
  • Technology succession issues from talent outflow
  • Rising testing and development costs
  • Competitive pressure from emerging biotech ventures
  • Increased development burdens from regulatory tightening

Innovations

2024: Completion of Next-Generation Antibody Production Platform

Overview
Built a high-speed production system utilizing proprietary antibody engineering technology.
Impact
Achieves shortened development periods and cost reductions.

2023: Initiation of Clinical Trials for Bispecific Antibodies

Overview
Started clinical trials for bispecific antibodies targeting cancer treatment.
Impact
A step toward practical application of innovative immunotherapy.

2022: Introduction of AI-Based Antibody Design

Overview
Improved antibody design precision by incorporating artificial intelligence technology.
Impact
Enhanced drug discovery efficiency and success rates.

2021: Development of Biomarker Detection System

Overview
Developed a biomarker system capable of high-precision evaluation of treatment efficacy.
Impact
Supports acceleration and optimization of clinical trials.

2020: Advancement in Antibody-Drug Delivery Technology

Overview
Succeeded in developing highly target-specific antibody-drug conjugates.
Impact
Aims to reduce side effects and improve therapeutic efficacy.

Sustainability

  • Introduction of energy-saving equipment in research facilities
  • Proper treatment and recycling promotion of biotech waste
  • Reagent procurement considering reduced environmental impact
  • Deployment of female researcher support programs
  • Health promotion activities through regional medical collaborations